Patents Examined by Taylor V. Oh
  • Patent number: 11987571
    Abstract: A ethyl 2-[9-(6-chloro-2-hydroxyquinolin-3-yl)-3,6-diphenyl-1,8-dioxo-3,4,9,10-tetrahydroacridine-10-yl]-acetate compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 2, 2023
    Date of Patent: May 21, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11981686
    Abstract: An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases, and the present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof, where each symbol in Formula (1) has the same definition as that described in the specification.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 14, 2024
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Junya Kawai, Osamu Iwamoto, Yuma Umezaki, Katsuyoshi Nakajima, Hiroyuki Tsuruoka, Keiji Saito, Nobuya Kurikawa, Natsumi Nishihama, Shinji Tanaka, Momoko Ogitani, Tomohiro Honda, Wataru Saitoh, Tsuyoshi Soneda, Nobuyuki Ohkawa
  • Patent number: 11981618
    Abstract: The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 14, 2024
    Assignee: AUTOTAC INC.
    Inventors: Yong Tae Kwon, Chang Hoon Ji, Srinivasrao Ganipisetti, Hee Yeon Kim, Su Ran Mun, Chan Hoon Jung, Eui Jung Jung, Ki Woon Sung
  • Patent number: 11976040
    Abstract: Provided herein are novel lipase inhibitors and methods for using the same to treat inflammation, multisystem organ failure, necrotic pancreatic acinar cell death, acute pancreatitis, sepsis (e.g., culture negative sepsis), burns, and acne. For example, provided herein are two novel lipase inhibitors useful in the methods described herein: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 3, 2023
    Date of Patent: May 7, 2024
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vijay P. Singh, Sampath-Kumar Anandan, Kevin Greenman, Zeeshan Kamal
  • Patent number: 11976043
    Abstract: A 3-cyano-2-ethoxy-9-(2-nitrobenzylidene)-4-(2-nitrophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridine compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: May 7, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Ibrahim Abdelhamid Mohamed Elshaer, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11970442
    Abstract: To achieve a method for producing a carbonic ester at a high yield by a simple process while suppressing formation of by-products, for example, a method for producing an aliphatic carbonic ester. The above problem is solved by a method for producing a carbonic ester, the method including a carbonic ester formation reaction in which an alcohol and carbon dioxide are reacted in the presence of an aromatic nitrile compound and a catalyst, wherein the water content in the alcohol used in the carbonic ester formation reaction is 0.10% by mass or less.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: April 30, 2024
    Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.
    Inventors: Hidefumi Harada, Takehiko Isobe, Hongyu Liu, Yousuke Shinkai, Ryotaro Umezu
  • Patent number: 11970455
    Abstract: A 7-(4-fluorobenzylidene)-4-(4-fluorophenyl)-2-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: December 8, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mohamed Gouda Mahmoud, Hany Mohamed Abd El-Latef Ahmed, Mai Mostafa Khalaf Ali, Saad Shaaban, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11970477
    Abstract: An 9-(2-hydroxyquinoline-3-yl)-10-[3-(dimethylamino)propyl]-3,4,6,7,9,10-hexahydroacridine-1,8(2H,5H)-dione compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: November 3, 2023
    Date of Patent: April 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed
  • Patent number: 11963949
    Abstract: The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ROS).
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: April 23, 2024
    Assignee: UNM RAINFOREST INNOVATIONS
    Inventors: Eric R. Prossnitz, Geetanjali Sharma, Matthias Barton, Matthias R. Meyer
  • Patent number: 11963950
    Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
    Type: Grant
    Filed: November 18, 2021
    Date of Patent: April 23, 2024
    Assignee: Loxo Oncology Inc.
    Inventors: Mark Reynolds, Charles Todd Eary
  • Patent number: 11958818
    Abstract: The present invention relates to compound of formula (I), wherein R1 is chloro, bromo iodo or a brosylate group. The present invention also relates to methods of making this compound and its use in carrying out organic transformations.
    Type: Grant
    Filed: April 29, 2020
    Date of Patent: April 16, 2024
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Nitinchandra D. Patel
  • Patent number: 11958816
    Abstract: A N?-({[(5-phenyl-1,3,4-oxadiazol-2-yl)sulfanyl]acetyl}oxy)benzenecarboximidamide compound, its synthesis, and its use as an antimicrobial agent.
    Type: Grant
    Filed: October 13, 2023
    Date of Patent: April 16, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11958808
    Abstract: An acetylsalicylic acid derivative and an application thereof. The present disclosure relates to the field of chemical pharmaceuticals, and in particular, to a compound shown in formula (I) or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: April 16, 2024
    Assignee: ZHEJIANG HANMAI PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventor: Jing Zhang
  • Patent number: 11952370
    Abstract: Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: April 9, 2024
    Assignees: Northeastern University, Indiana University Research and Technology Corporation
    Inventors: Ganeshsingh A. Thakur, Diomedes E. Logothetis, Lucas Cantwell, Yu Xu, Anantha Shekhar
  • Patent number: 11951089
    Abstract: Provided is a method for preventing or treating a wound or scar comprising administering to a subject in need thereof a pharmaceutical composition comprising benzbromarone as an active ingredient, wherein benzbromarone inhibits the function of heat shock protein 47 (HSP47), or inhibits the accumulation of collagen by reducing collagen overproduction cells.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: April 9, 2024
    Assignee: INNOVO THERAPEUTICS INC.
    Inventors: Dong Chul Lim, Jung Gyu Park
  • Patent number: 11952356
    Abstract: A crystalline form I of 1,4-BIS[1,2-BENZISOSELENAZOL-3(2H)-one]-butane has characteristic peaks at 2? angles of 6.17±0.20°, 12.28±0.20°, 18.44±0.20°, 25.92±0.20° and 30.95±0.20° by X-ray powder diffraction using Cu-K? radiation.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: April 9, 2024
    Assignee: SHANGHAI YUANXI MEDICINE CORP.
    Inventors: Huihui Zeng, Hanwei Yin
  • Patent number: 11945814
    Abstract: Diphosphate salts of N2-(2-ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine, and crystalline forms thereof, processes for the preparation of the new salt forms; and their use as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: April 2, 2024
    Assignee: CRT Pioneer Fund LP
    Inventors: Julian S. Northen, John Mykytiuk, Gillian Moore
  • Patent number: 11945800
    Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((5-oxo-2-phenyl-4-(quinolin-2-ylmethylene)-4,5-dihydro-1H-imidazol-1-yl)methyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or anti-inflammatory agent.
    Type: Grant
    Filed: September 21, 2023
    Date of Patent: April 2, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
  • Patent number: 11939314
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 26, 2024
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
  • Patent number: 11939421
    Abstract: A curative system comprising a combination of adipic acid dihydrazide and/or isophthalic dihydrazide and a clathrate in which the guest compound of the clathrate comprises an imidazole, an imidazoline or diazabicycloalkanes (DBCA).
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: March 26, 2024
    Assignee: HEXCEL COMPOSITES LIMITED
    Inventors: Christopher Robert Mason, Nicholas Verge